Modulation of nuclear-retained RNA

Inactive Publication Date: 2013-08-29
IONIS PHARMA INC
View PDF4 Cites 38 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes methods for treating diseases or disorders caused by aberrant RNA in tissues with low antisense oligonucleotide uptake. The methods involve administering chemically-modified antisense oligonucleotides to an animal to activate a nuclear ribonuclease that can target and cleave the aberrant RNA. This approach has shown promise in animal models and could potentially be developed into a therapeutic strategy for humans with these disorders.

Problems solved by technology

The mutation is unstable in dividing and post-mitotic cells, with a bias towards further expansion.
This interaction causes retention of CUGexp RNA in nuclear foci, which adversely effects transcriptional and post-transcriptional regulation of other genes.
Treatment of the disease is complicated because the drug or agent must be taken up by muscle tissue.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modulation of nuclear-retained RNA
  • Modulation of nuclear-retained RNA
  • Modulation of nuclear-retained RNA

Examples

Experimental program
Comparison scheme
Effect test

example 1

Antisense Inhibition of Human MALAT1 in A549 Cells

[0321]Antisense oligonucleotides targeted to a metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) nucleic acid, a non-coding nuclear-retained RNA transcript, were tested for their effect on MALAT1 RNA transcript in vitro. Cultured A549 cells at a density of 5,000 cells per well were transfected using Lipofectin reagent with 60 nM antisense oligonucleotide. After approximately 24 hours, RNA was isolated from the cells and MALAT1 RNA transcript levels were measured by quantitative real-time PCR. The human primer probe set RTS2736 (forward sequence AAAGCAAGGTCTCCCCACAAG, designated herein as SEQ ID NO: 89; reverse sequence TGAAGGGTCTGTGCTAGATCAAAA, designated herein as SEQ ID NO: 90; probe sequence TGCCACATCGCCACCCCGTX, designated herein as SEQ ID NO: 91) was used to quantitated MALAT1 RNA. MALAT1 RNA transcript levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent ...

example 2

Antisense Inhibition of Human MALAT1 in A549 Cells

[0323]Antisense oligonucleotides targeted to a MALAT1 nucleic acid were tested for their effects on MALAT1 RNA in vitro. Cultured A549 cells at a density of 5,000 cells per well were transfected using Lipofectin reagent with 150 nM antisense oligonucleotide. After approximately 24 hours, RNA was isolated from the cells and MALAT1 RNA transcript levels were measured by quantitative real-time PCR. Human primer probe set RTS2736 was used to quantitate MALAT1 RNA. MALAT1 RNA transcript levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of MALAT1, relative to untreated control cells.

[0324]The antisense oligonucleotides in Table 4 are 5-10-5 gapmers, where the gap segment comprises ten 2′-deoxynucleosides and each wing segment comprises five 2′-MOE nucleosides. Each nucleotide in the 5′ wing segment and each nucleotide in the 3′ wing segment has a 2′-MOE modification....

example 3

Dose-Dependent Antisense Inhibition of Human MALAT1 in A549 Cells

[0325]Several of the antisense oligonucleotides exhibiting in vitro inhibition of MALAT1 in A549 cells (see Example 2) were tested at various doses. Cells were plated at a density of 5,000 cells per well and transfected using Lipofectin reagent with 7.5 nM, 15 nM, 30 nM, and 60 nM concentrations of each antisense oligonucleotide. After approximately 16 hours, RNA was isolated from the cells and MALAT1 RNA transcript levels were measured by quantitative real-time PCR using primer probe set RTS2736 MALAT1 RNA transcript levels were normalized to total RNA content, as measured by RIBOGREEN®. Results are presented in Table 5 as percent inhibition of MALAT1, relative to untreated control cells.

TABLE 5Dose-dependent antisense inhibition of human MALAT1 in A549 cellstested with primer probe set RTS2736ISISIC50No.7.5 nM15 nM30 nM60 nM(nM)395240678190961.83952433154809313.1395244767386910.5395248437087938.1395251577384904.03952...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Volumeaaaaaaaaaa
Login to View More

Abstract

Provided herein are methods, compounds, and compositions for reducing expression of a nrRNA in an animal. Also provided herein are methods, compounds, and compositions for treating, ameliorating, delaying or reducing a symptom of a disease or disorder associated with a nuclear-retained RNA in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a disease or condition associated with a nuclear-retained RNA, or a symptom thereof.

Description

SEQUENCE LISTING[0001]The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled BIOL0133WOSEQ.txt created Jul. 19, 2011, which is approximately 724 kb in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.FIELD OF THE INVENTION[0002]Provided herein are methods of achieving a pharmacologically relevant reduction of nuclear-retained RNAs and RNAs having a long residence time in the nucleus in a tissue having low antisense oligonucleotide uptake. Such methods are useful, for example, for treating, ameliorating, delaying or reducing a symptom of a disease or disorder in an animal associated with nuclear-retained RNAs and RNAs having a long residence time in the nucleus.BACKGROUND[0003]Systemic administration of antisense oligonucleotides produces high tissue concentration in liver and renal cortex, and moderate levels in some other ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/113
CPCC12Y207/11C12N15/113C12N2310/11C12N2310/315C12N2310/3181C12N2310/3231C12N2310/3341C12N2310/341C12N2310/346C12N15/1137C12N2310/321C12N2310/3525C12N2310/322C12N2310/3533C12N2310/3527A61P15/00A61P21/00A61P21/04A61P25/14A61P25/18A61P35/00A61P43/00A61K31/7088A61K48/00
InventorBENNETT, C. FRANK
OwnerIONIS PHARMA INC